{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:11:39Z","timestamp":1774476699409,"version":"3.50.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT scan is not the preferred modality to evaluate prostate cancer patients due to generally low uptake of FDG in prostate cancer cells, it can still be helpful in some selected cases with diagnostic dilemma. Here we are presenting an unusual prostate cancer case, status post radical prostatectomy, with heterogenous uptake in osseous lesions on\n                    <jats:sup>68<\/jats:sup>\n                    Ga-PSMA PET\/CT scan and low PSA values. He was referred for further evaluation with\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT scan, revealing widely metastatic lesions in bone and liver, in addition to mildly avid recurrence in prostatectomy surgical bed and also metastasis in the spleen.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000005518","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T12:02:29Z","timestamp":1732190549000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["FDG PET\/CT Scan Still Can Help in Evaluation of Prostate Cancer"],"prefix":"10.1097","author":[{"given":"Abtin","family":"Doroudinia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"bib1-20251117","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.semnuclmed.2023.06.005","article-title":"Role of FDG PET\/CT in management of patients with prostate cancer","volume":"54","year":"2024","journal-title":"Semin Nucl Med"},{"key":"bib2-20251117","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40644-015-0038-0","article-title":"FDG-PET\/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy","volume":"15","year":"2015","journal-title":"Cancer Imaging"},{"key":"bib3-20251117","first-page":"301","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography (PET\/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy","volume":"15","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"bib4-20251117","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.euf.2018.03.008","article-title":"Increased prostate cancer glucose metabolism detected by 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in localised Gleason 8-10 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration","volume":"5","year":"2019","journal-title":"Eur Urol Focus"},{"key":"bib5-20251117","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1007\/s00259-021-05221-6","article-title":"Diagnostic value of 18F-FDG PET\/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET\/CT","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20251117","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40644-023-00599-y","article-title":"Meta-analysis of 18F-PSMA-1007 PET\/CT, 18F-FDG PET\/CT, and 68Ga-PSMA PET\/CT in diagnostic efficacy of prostate cancer","volume":"23","year":"2023","journal-title":"Cancer Imaging"},{"key":"bib7-20251117","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"key":"bib8-20251117","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20251117","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1053\/j.semnuclmed.2016.07.004","article-title":"Is there use for FDG-PET in prostate cancer?","volume":"46","year":"2016","journal-title":"Semin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:00:28Z","timestamp":1763420428000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":9,"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005518","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,18]]}}}